ClinicalTrials.gg
DrugBiological

Autologous Bispecific BCMA/CD19-targeted CAR-T Cells GC012F clinical trials

Also written AZD0120 and GC012F.

studies test it
29
open now
21
in phase 3
3
first study started
2020

How each study uses Autologous Bispecific BCMA/CD19-targeted CAR-T Cells GC012F is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the Autologous Bispecific BCMA/CD19-targeted CAR-T Cells GC012F studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
Not in FDA's approval records
European Union
Not in EMA's list of EU-wide authorizations

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

GC012F injection
13
GC012F CAR-T Cell Injection
3
CD19-BCMA CAR-T cells
2

Development codes

AZD0120
11
GC012F
3

Studies by the year they started

28 studies that test it; most in 2025 (9); 1 more planned to start later

Studies that test Autologous Bispecific BCMA/CD19-targeted CAR-T Cells GC012F, by start year
YearStudies
20201
20212
20221
20235
20242
20259
20268

By phase

A phase 1/2 study counts in both.

Early Phase 1
12
Phase 1
14
Phase 2
7
Phase 3
3

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Who runs them

Industry 12 · Other 17

AstraZeneca (8) · Shanghai Changzheng Hospital (5) · Gracell Biotechnologies (Shanghai) Co., Ltd. (3) · Daishi Tian (3) · Zhejiang University (2) · Saurabh Dahiya (1) · Qiong Fu (1) · Chongbo Zhao (1)

Often tested with

Tested in the same studies.

Cyclophosphamide (1)

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Reaching primary completion within a year · 8

Studies that test Autologous Bispecific BCMA/CD19-targeted CAR-T Cells GC012F.

Studies

Open first, then newest update. How each study uses Autologous Bispecific BCMA/CD19-targeted CAR-T Cells GC012F is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 29

See all 29 studies that test Autologous Bispecific BCMA/CD19-targeted CAR-T Cells GC012F →